Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real-world finding.

After matching, adalimumab still realizes a higher rate of clinical response than etanercept to some extent with equivalent safety in rheumatoid arthritis patients adalimumab efficacy etanercept rheumatoid arthritis safety In the matched cohort, the DAS28 ESR also showed a decreasing trend from W0 to W24 in the ADA group ( p < .001) and the ETN group ( p < .001).

also in 13,073 other papers